Peptide harm reduction: difference between revisions
Diff·revision 15 → 16·09:36, 6 May 2025
Difference between revision 15 and revision 16 of Peptide harm reduction. 3 lines changed; the page grew by 507 bytes.
| Revision 15 — 03:16, 21 Apr 2025 PatientPanelPru (talk) attribute the affordability estimate to the analysis it comes from 3,468 bytes +30 | Revision 16 — 09:36, 6 May 2025 HarmReductionHen (talk) fix a dangling clause 3,975 bytes +507 | ||
|---|---|---|---|
| 33 | [[Third-party testing|Independent testing]] narrows them further for the sample tested, subject to the sampling and custody limitations set out at [[Blind sampling]] and [[Chain of custody]]. | 33 | [[Third-party testing|Independent testing]] narrows them further for the sample tested, subject to the sampling and custody limitations set out at [[Blind sampling]] and [[Chain of custody]]. |
| 34 | 34 | ||
| + | 35 | What no document addresses is the absence of clinical oversight — no diagnosis, no monitoring, no clinician aware of the exposure if something goes wrong, and no adverse-event reporting route.{{r|ada2024}} That is a structural feature of unregulated supply rather than a documentation gap. See [[Aspiration risk under anaesthesia]] for one concrete instance.{{r|marlatt1996}} | |
| + | 36 | ||
| 35 | == References == | 37 | == References == |
| 36 | {{reflist}} | 38 | {{reflist}} |
| ⋮ | ⋮ | ||
| 38 | <ref name="usp1503">United States Pharmacopeia, General Chapter <1503>, ''Quality Attributes of Synthetic Peptide Drug Substances''.</ref> | 40 | <ref name="usp1503">United States Pharmacopeia, General Chapter <1503>, ''Quality Attributes of Synthetic Peptide Drug Substances''.</ref> |
| 39 | <ref name="reports">PeptidePedia Wiki community test-report tally, 2024–2026 (self-reported; see [[Project:Sourcing_guidelines]]).</ref> | 41 | <ref name="reports">PeptidePedia Wiki community test-report tally, 2024–2026 (self-reported; see [[Project:Sourcing_guidelines]]).</ref> |
| + | 42 | <ref name="ada2024">American Diabetes Association. "Standards of Care in Diabetes." ''Diabetes Care'' 47(Suppl 1) (2024).</ref> | |
| 40 | 43 | ||
| 41 | == See also == | 44 | == See also == |